CN113813221B - 一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 - Google Patents
一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 Download PDFInfo
- Publication number
- CN113813221B CN113813221B CN202111271947.2A CN202111271947A CN113813221B CN 113813221 B CN113813221 B CN 113813221B CN 202111271947 A CN202111271947 A CN 202111271947A CN 113813221 B CN113813221 B CN 113813221B
- Authority
- CN
- China
- Prior art keywords
- aging
- soluble
- skin wrinkle
- molecular weight
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 59
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 239000000017 hydrogel Substances 0.000 claims abstract description 30
- 230000037303 wrinkles Effects 0.000 claims abstract description 21
- 230000003796 beauty Effects 0.000 claims abstract description 18
- 235000006965 Commiphora myrrha Nutrition 0.000 claims abstract description 16
- 235000007265 Myrrhis odorata Nutrition 0.000 claims abstract description 16
- 240000007311 Commiphora myrrha Species 0.000 claims abstract description 15
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 11
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 11
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 11
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 11
- LODWEXDBRZBADB-XEVVZDEMSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-(hexadecanoylamino)hexanoyl]amino]-3-methylbutanoyl]amino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O LODWEXDBRZBADB-XEVVZDEMSA-N 0.000 claims abstract description 10
- 229940094912 palmitoyl tripeptide-5 Drugs 0.000 claims abstract description 10
- 150000001408 amides Chemical class 0.000 claims abstract description 9
- 239000000835 fiber Substances 0.000 claims abstract description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 31
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 24
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 24
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002537 cosmetic Substances 0.000 claims description 17
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000004745 nonwoven fabric Substances 0.000 claims description 11
- 230000001681 protective effect Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000002313 adhesive film Substances 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- -1 dihydroxyglycine aluminum Chemical compound 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 5
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 3
- 240000001341 Reynoutria japonica Species 0.000 claims description 3
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 229940059958 centella asiatica extract Drugs 0.000 claims description 3
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 3
- 239000013081 microcrystal Substances 0.000 claims description 2
- 239000002985 plastic film Substances 0.000 claims description 2
- 229920006255 plastic film Polymers 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229940092665 tea leaf extract Drugs 0.000 claims description 2
- 210000003491 skin Anatomy 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 26
- 210000004027 cell Anatomy 0.000 abstract description 13
- 108010035532 Collagen Proteins 0.000 abstract description 6
- 102000008186 Collagen Human genes 0.000 abstract description 6
- 229920001436 collagen Polymers 0.000 abstract description 6
- 210000004207 dermis Anatomy 0.000 abstract description 6
- 230000007794 irritation Effects 0.000 abstract description 6
- 210000002510 keratinocyte Anatomy 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000037394 skin elasticity Effects 0.000 abstract description 5
- 210000000434 stratum corneum Anatomy 0.000 abstract description 5
- 230000000946 synaptic effect Effects 0.000 abstract description 4
- 239000000243 solution Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 9
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000208229 Burseraceae Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 240000009023 Myrrhis odorata Species 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法。该微针贴膜组合物包括基座和位于基座上的针体及舒缓和固定针体作用的水凝胶贴膜,该针体内包埋有肌肤祛皱、抗衰老组合物:玻色因0.1‑0.5%、棕榈酰三肽‑5 0.01‑0.1%、二肽二氨基丁酰卞基酰胺二乙酸盐0.1‑5%、没药叶细胞提取物0.2‑0.5%。本发明所述组合物既能促进基底层角质细胞的增殖又能放松肌肉,调控突触信号及时祛皱,还能生成和保护胶原蛋白,增加皮肤结构凝聚力恢复真皮纤维网络结构,多通路协同增效增加皮肤弹性、减少皱纹。本发明将肌肤祛皱、抗衰老组合物包埋在玻尿酸可溶微针针体内,具有提高活性组分的透皮吸收性、缓释性和降低刺激性的作用,进一步提升祛皱、抗衰老功效。
Description
技术领域
本发明涉及一种护肤品及其制备方法,属于日用化学品技术领域,尤其是涉及一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法。
背景技术
自然界所有生物都遵循从出生﹑生长﹑发育﹑成熟﹑衰老直至死亡的过程,人类也是同样如此。随着年龄增长,在达到成熟期以后,人体开始生理上的衰老,身体各个部位的结构和功能不断变化,其中皮肤的衰老最为明显,皮肤失去弹性,出现明显的皱纹,尤其是脸部,这是所有爱美人士不愿意看到和接受的。皮肤衰老是人体衰老固有的生理机制和风吹日晒、环境污染等外界因素共同作用的结果。衰老虽然不可阻挡,但我们可通过一些手段来减缓它的步伐,给皮肤适时补充养分来抑制皮肤的过早衰老,抗衰老化妆品就这样应运而生。
目前市场上的抗衰老类产品主要有两种形式:1)外用化妆品,通过添加一些具有补充胶原蛋白、清除自由基或促进细胞新陈代谢等活性物来改善皮肤衰老;2)表皮填充,主要有类肉毒杆菌、透明质酸、微晶瓷或聚左旋乳酸等对皮肤进行注射填充。然而,第一种方式由于我们皮肤表面存在天然的皮肤屏障,外用护肤品中有效活性物质的吸收率很低,效果不明显,作用时间长。第二种方式需要找专业人员操作,过程疼痛,可能有不良反应,维持时间有限,成本高,同时治标不治本。
因此,开发一种安全高效、刺激性小、功效明显且稳定的祛皱抗衰老产品是非常有必要的。
发明内容
为了克服上述现有技术存在的问题,本发明的目的是提供一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物,本发明将肌肤祛皱、抗衰老组合物包埋在玻尿酸可溶微针针体内,具有提高活性组分的透皮吸收性、缓释性和降低刺激性的作用,进一步提升祛皱、抗衰老功效。
本发明的另一目的是提供一种上述肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,简单,能耗小,生产成本低,易于实现连续化大量生产。
本发明是采用以下的技术方案来实现的。
一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物,包括基座和位于基座上的针体及舒缓和固定针体作用的水凝胶贴膜;所述针体内包埋有肌肤祛皱、抗衰老组合物,按微针的总重量百分比计,该肌肤祛皱、抗衰老组合物包含:
玻色因0.1-0.5%,棕榈酰三肽-5 0.01-0.1%,二肽二氨基丁酰卞基酰胺二乙酸盐0.1-5%,没药叶细胞提取物0.2-0.5%。
作为优选,按微针的总重计,所述肌肤祛皱、抗衰老组合物包括如下重量百分比的组分:
玻色因0.1-0.3%,棕榈酰三肽-5 0.01-0.06%,二肽二氨基丁酰卞基酰胺二乙酸盐0.1-3%,没药叶细胞提取物0.2-0.4%。
作为优选,所述肌肤祛皱、抗衰老组合物的制备还包括以下重量百分比的组分:
5-15%的甘油、2-5%的低分子量的透明质酸钠和10-15%的高分子量的透明质酸钠。
作为优选,所述可溶美容微针呈圆锥形,主要成分为玻尿酸,针头长度为150-450μm,微针间距为400-700μm,整个干片包含透明质酸微晶支柱1000-3000个。
作为优选,所述水凝胶贴膜有4层,组分有15-25种;水凝胶贴膜自上而下是由无纺布、水凝胶体、活性组分层和保护薄膜组成。
该无纺布为非织造布,是利用高聚物切片、短纤维或长丝固结而成的。
按照水凝胶贴膜的总重计,该水凝胶体具体成分为:5-15%的甘油、1-2%的聚丙烯酸钠、1-3%的二羟基甘氨酸铝、0.5-2%的纤维素胶、2-5%的酒石酸、5-15%的丁二醇和50-80%的水。
按照水凝胶贴膜的总重计,该活性组分层具体成分为:
0.1-2%的积雪草提取物,0.2-3%的虎杖根提取物,0.2-3%的黄芩根提取物,0.1-2%的茶叶提取物,0.2-3%的光果甘草根提取物,0.3-1%的母菊花提取物,0.1-2%的迷迭香叶提取物组成。
该保护薄膜具体为一层白色的塑料膜。
另一方面,本发明提供了一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,包括以下步骤:
1)粘稠性液体的制备:
将肌肤祛皱、抗衰老组合物加入余量水中,搅拌溶解,再加入甘油5-15%、透明质酸钠(低分子量)2-5%和透明质酸钠(高分子量)10-15%,继续搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体。
2)可溶美容微针的制备:
将上述粘稠性液体注入微针模具中,干燥脱模后得到可溶美容微针。
3)水凝胶贴膜的制备:
将1-2%的聚丙烯酸钠和1-3%的二羟基甘氨酸铝混合均匀,加入5-15%的甘油和5-15%的丁二醇充分搅拌,获得A相溶液;
将0.5-2%的纤维素胶加到水中搅拌后加入2-5%的酒石酸,再加入活性组分层,搅拌至充分溶解,获得B相溶液;
将B相溶液加入A相溶液中,真空搅拌获得水凝胶膏体,最后在涂布机上和无纺布、保护薄膜一起进行涂布,制得水凝胶贴膜。
作为优选,步骤1)中,所述低分子量的透明质酸钠的分子量为2000-10000道尔顿;所述高分子量的透明质酸钠的分子量为40-100万道尔顿。
该高分子量的透明质酸钠和低分子量的透明质酸钠的质量比为1:3.0-5.0。
作为优选,步骤2)中,所述微针模具包含正方形、矩形或弧形,也可做成成本较高的面膜型。
作为优选,所述干燥的温度为室温,湿度为15-25%,干燥的时间为12-24h。
作为优选,步骤3)中,所述真空搅拌的搅拌速度为50-120r/min,搅拌时间为5-15min。
借由上述技术方案,本发明具有如下有益技术效果:
1)本发明所述肌肤祛皱、抗衰老可溶美容微针贴膜组合物既能促进基底层角质细胞的增殖又能放松肌肉,调控突触信号及时祛皱,还能生成和保护胶原蛋白,增加皮肤结构凝聚力恢复真皮纤维网络结构,多通路协同增效增加皮肤弹性、减少皱纹。
2)本发明将祛皱、抗衰老组合物包埋在玻尿酸可溶微针针体内,具有提高活性组分的透皮吸收性、缓释性和降低刺激性的作用,进一步提升祛皱、抗衰老功效。
附图说明
图1是本发明提供的一种肌肤祛皱、抗衰老可溶美容微针的结构图。
图2是本发明提供的一种肌肤祛皱、抗衰老可溶美容微针的祛皱效果图。
具体实施方式
下面通过具体较佳实施例,对本发明的技术方案作进一步具体的说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
如图1结构图所示,本发明公开了一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及制备方法。该微针贴膜组合物包括基座和位于基座上的针体及舒缓和固定针体作用的水凝胶贴膜,基座是由玻尿酸组成。该针体内包埋有肌肤祛皱、抗衰老组合物,其组成包含:
玻色因0.1-0.5%,棕榈酰三肽-5 0.01-0.1%,二肽二氨基丁酰卞基酰胺二乙酸盐0.1-5%,没药叶细胞提取物0.2-0.5%。
水凝胶贴膜自上而下是由无纺布、水凝胶体、活性组分层和保护薄膜组成。无纺布的作用是提高贴膜的透气性,水凝胶体的作用是长时间锁水,活性组分层的作用是缓释水分、辅助保湿和缓解刺激抗敏感,保护薄膜的作用是防止凝胶营养和水分流失。
以下重点介绍一下组合物原料成分功效说明。
①玻色因
玻色因是从天然木糖衍生而来的一种生物活性物质,可以刺激氨基葡聚糖(GAGs)的生成,还可以防止皮肤中的水分流失。玻色因进入皮肤,促进细胞外基质中称为蛋白质多糖(proteoglycans)的生成和构建。这些分子吸收水分,使基质呈凝胶状,增加细胞及皮肤的紧致度。它还可以作为指引修复分子(譬如细胞生长的蛋白质)通行的通道,改善真皮与表皮间的粘合度,维持真皮的弹性,预防皮肤老化。
②棕榈酰三肽-5
棕榈酰三肽-5可以促进肌肤细胞生长,抑制氧自由基和羟基自由基,促进基质蛋白尤其是胶原蛋白的合成,同时还可增加弹性蛋白、透明质酸、糖胺聚糖和纤维连接蛋白的生成,从而起到抗皱紧致皮肤的作用。
③二肽二氨基丁酰卞基酰胺二乙酸盐
二肽二氨基丁酰卞基酰胺二乙酸盐是一种神经肽类,其美容功效模仿蛇毒毒素Waglerinl,通过与乙酰胆碱竞争肌细胞膜上的受体,阻止乙酰胆碱与肌细胞结合,使得肌肉不能收缩,处于放松状态,达到抚平皱纹的美容目的。
④没药叶细胞提取物
没药为橄榄科植物地丁树或哈地丁树的干燥树脂,在东方是一种活血、化瘀、止痛、健胃的中药。没药中富含黄酮类化合物,具有消除氧化自由基,抗氧化,抗菌,抗病毒等作用。没药叶细胞提取物能促进皮肤新陈代谢,抗衰老,促进基底层角质细胞的增殖。
因此,由上述四种成分组合而成的组合物既能促进基底层角质细胞的增殖;又能放松肌肉,调控突触信号,及时祛皱;还能生成和保护胶原蛋白,增加皮肤结构凝聚力恢复真皮纤维网络结构,多通路协同增效增加皮肤弹性、减少皱纹,最终达到稳定的祛皱效果。
本发明将肌肤祛皱、抗衰老组合物包埋在玻尿酸可溶微针针体内,具有提高活性组分的透皮吸收性、缓释性和降低刺激性的作用,进一步提升祛皱、抗衰老功效。
以下百分比含量均为重量百分比含量。本发明所有的原料成分均为市售商品。玻色因购自上海克琴科技有限公司、棕榈酰三肽-5和二肽二氨基丁酰卞基酰胺二乙酸盐购自帝斯曼、没药叶细胞提取物购自Naolys。
没药叶细胞提取物的制备方法为先将没药叶烘干并粉碎;再将没药叶、纤维素酶、吐温-80和水混合均匀,在(40-70)℃温度和真空下反应,过滤得到浓缩液;接着采用微波法对浓缩液进行提取;最后过滤并烘干滤渣,磨成粉末得到没药叶细胞提取物。
积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物和迷迭香叶提取物都购自北京工商大学或者迦叶生物科技有限公司。
实施例1
一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,包括以下步骤:
1)粘稠性液体的制备:
将0.3%玻色因,0.05%棕榈酰三肽-5,1%二肽二氨基丁酰卞基酰胺二乙酸盐,0.4%没药叶细胞提取物加入余量水中,搅拌溶解,再加入10%甘油、3%透明质酸钠(分子量为5000道尔顿)和12%透明质酸钠(分子量为60万道尔顿),继续搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体。
2)可溶美容微针的制备:
将上述粘稠性液体注入正方形微针模具中,室温、湿度为20%条件下干燥20h,脱模后得到可溶美容微针。
3)水凝胶贴膜的制备:
将1.5%聚丙烯酸钠和2%二羟基甘氨酸铝混合均匀,加入10%甘油和10%丁二醇充分搅拌,获得A相溶液;
将1%纤维素胶加到水中搅拌后加入3%酒石酸,再加入0.6%积雪草提取物、0.5%虎杖根提取物,0.5%黄芩根提取物、0.6%茶叶提取物、0.8%光果甘草根提取物、0.8%母菊花提取物和0.5%迷迭香叶提取物,搅拌至充分溶解,获得B相溶液;
将B相溶液加入A相溶液中,真空搅拌获得水凝胶膏体,搅拌速度为80r/min,搅拌时间为10min,最后在涂布机上和无纺布、保护薄膜一起进行涂布,制得水凝胶贴膜。
实施例2
一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,包括以下步骤:
将0.2%玻色因,0.03%棕榈酰三肽-5,0.8%二肽二氨基丁酰卞基酰胺二乙酸盐,0.3%没药叶细胞提取物加入余量水中,搅拌溶解,再加入10%甘油、3%透明质酸钠(分子量为5000道尔顿)和12%透明质酸钠(分子量为60万道尔顿),继续搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体。
2)可溶美容微针的制备:
同实施例1。
3)水凝胶贴膜的制备:
同实施例1。
实施例3
一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,包括以下步骤:
1)粘稠性液体的制备:
将0.1%玻色因,0.01%棕榈酰三肽-5,0.5%二肽二氨基丁酰卞基酰胺二乙酸盐,0.2%没药叶细胞提取物加入余量水中,搅拌溶解,再加入10%甘油、3%透明质酸钠(分子量为5000道尔顿)和12%透明质酸钠(分子量为60万道尔顿),继续搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体。
2)可溶美容微针的制备:
同实施例1。
3)水凝胶贴膜的制备:
同实施例1。
空白例1
一种可溶美容微针贴膜组合物的制备方法,包括以下步骤:
1)粘稠性液体的制备:
将10%甘油、3%透明质酸钠(分子量为5000道尔顿)和12%透明质酸钠(分子量为60万道尔顿)加入余量水中,搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体。
2)可溶美容微针的制备:
同实施例1。
3)水凝胶贴膜的制备:
同实施例1。
效果验证试验例
一、抗衰老功效分析实验
肌肤祛皱、抗衰老组合物对基质金属蛋白酶-1(MMP-1酶)的影响:配制50mmol/L的HEPES缓冲液;将MMP-1酶原用缓冲液稀释至0.22μg/100μL备用;将荧光底物DQ-gelatin用缓冲液稀释至0.20μg/100μL备用;配制30mmol/L的酶原激活剂APMA储备液备用;将实施例1、2、3和空白例1所制的粘稠性液体配制成1mg/ml浓度的分散液备用;将MMP-1酶原溶液和APMA溶液按10:1的体积比混合,在37℃孵育45min活化;取活化后的MMP-1溶液(浓度为0.20μg/100μL)40μL加入96孔酶标板中,再分别加入组合物分散液溶液8μL,并设置去离子水组别为空白对照组,荧光底物DQ-gelatin溶液52μL,使最终反应体系为100μL;将完成加样的96孔酶标板放入37℃培养箱中恒温孵育600s。
试验结果检测:
(1)反应前在激发波长为460nm,发射波长为520nm的检测条件下检测组合物成分的荧光强度;
(2)反应体系停止孵育后立即用荧光酶标仪检测整个反应体系的荧光强度,激发波长为460nm,发射波长为520nm。
试验数据处理:MMP-1抑制百分数(%)=[1-(A1-A2)/A0]×100%,A1-添加含肌肤祛皱、抗衰老组合物的粘稠性液成分抑制组的荧光强度;A2-含肌肤祛皱、抗衰老组合物的粘稠性液成分自身的荧光强度;A0-空白对照组的荧光强度。结果如下表1所示。
表1测试结果
实施例1 | 实施例2 | 实施例3 | 空白例1 | 空白对照组 | |
抑制率% | 38.25 | 33.54 | 28.76 | 0.38 | 0.15 |
由表1可以看出,本发明实施例1-3所得含肌肤祛皱、抗衰老组合物的粘稠性液体可以有效抑制基质金属蛋白酶-1的活性,而空白例1所得不含肌肤祛皱、抗衰老组合物的粘稠性液体抑制能力很弱。说明肌肤祛皱、抗衰老组合物具有抗衰老效果。
二、协同增效实验例
对比例1-4
一种可溶美容微针贴膜组合物的粘稠性液体组分配比,如下表2-3所示:
表2粘稠性液体组分配比(重量百分含量%)
表3粘稠性液体组分配比(重量百分含量%)
制备工艺同实施例1所述。
实施例1、对比例1-14及空白例1进行祛皱效果测试。
受试人员160人,每组10人,受试人员1天内面部使用1次,每次时间1-2小时,连续使用1个月。
皮肤皱纹采用德国CK公司的皮肤弹性测试仪MPA580,并使用Reviscometer RV600探头测得。
测试效果如下表4所示
表4测试结果
由表4中试验数据可以看出,祛皱效果排序为实施例1>对比例11、12、13、14>对比例5、6、7、8、9、10>对比例1、2、3、4,证明了肌肤祛皱、抗衰老组合物通过组分之间的协同作用,比单纯的一种,两种或三种成分组合具有更好的祛皱效果。
三、人体试用评价实验
实验方法:选取实施例1、2、3和空白例1中制备的肌肤祛皱、抗衰老可溶美容微针贴膜组合物作为实验样品,分别给志愿者进行试用评价。选取80名40-60岁的志愿者,男女各40人,随机分成4组,每组10名男性,10名女性。
4组志愿者分别使用实施例1、2、3和空白例1中制备的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的样品。
使用方法:洁面后使用,每天使用一次,每次时间1-2小时,连续使用4周,根据皱纹改善情况进行感官评价。评分标准为1分-没有效果,2分-有效果、很弱,3分-有效果、效果明显,4分-有效果、效果较好,5分-有效果、效果非常好。评分“≥3分”判断为效果明显,并统计出每组中评分“≥3分”的比例。得到的结果如表4所示:
表5测试结果
评价结果 | 祛皱效果明显 | 有效果 | 无效果 |
实施例1 | 70% | 20% | 10% |
实施例2 | 60% | 30% | 10% |
实施例3 | 50% | 30% | 20% |
空白例1 | 0 | 10% | 90% |
由表5可以看出,本发明实施例1-3所得的肌肤祛皱、抗衰老可溶美容微针贴膜组合物可有效祛皱,效果优于空白例1的不含肌肤祛皱、抗衰老组合物的可溶美容微针贴膜组合物。
实施例1的祛皱效果如图2所示。
综上所述,本发明的肌肤祛皱、抗衰老组合物既能促进基底层角质细胞的增殖;又能放松肌肉,调控突触信号,及时祛皱;还能生成和保护胶原蛋白,增加皮肤结构凝聚力恢复真皮纤维网络结构,多通路协同增效增加皮肤弹性、减少皱纹,最终达到稳定的祛皱效果。
本发明将祛皱、抗衰老组合物包埋在玻尿酸可溶微针针体内,具有提高活性组分的透皮吸收性、缓释性和降低刺激性的作用,进一步提升祛皱、抗衰老功效。水凝胶贴膜配合可溶性微针使用,缺水时会释放其本身的水分,并具有自粘性、低致敏性,能将可溶美容微针覆盖在皮肤上不易脱落,保证了微针的祛皱、抗衰老效果稳定发挥。
以上所述仅为本发明的较佳实施例,并非对本发明作任何形式上的限制,在不超出权利要求所记载的技术方案的前提下还有其它的变体及改型。
Claims (8)
1.一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物,其特征在于:包括基座和位于基座上的针体及舒缓和固定针体作用的水凝胶贴膜;
所述针体内包埋有肌肤祛皱、抗衰老组合物,按微针的总重量百分比计,该肌肤祛皱、抗衰老组合物包含:
玻色因0.1-0.3%,棕榈酰三肽-5 0.01-0.05%,二肽二氨基丁酰卞基酰胺二乙酸盐0.5-1%,没药叶细胞提取物0.2-0.4%,甘油5-15%,低分子量的透明质酸钠2-5%和高分子量的透明质酸钠10-15%;所述低分子量的透明质酸钠的分子量为2000-10000道尔顿;所述高分子量的透明质酸钠的分子量为40-100万道尔顿;
所述水凝胶贴膜有4层,组分有15-25种;所述水凝胶贴膜自上而下是由无纺布、水凝胶体、活性组分层和保护薄膜组成;
按照水凝胶贴膜的总重计,所述活性组分层具体成分为:
0.1-2%的积雪草提取物,0.2-3%的虎杖根提取物,0.2-3%的黄芩根提取物,0.1-2%的茶叶提取物,0.2-3%的光果甘草根提取物,0.3-1%的母菊花提取物,0.1-2%的迷迭香叶提取物组成;
所述可溶美容微针呈圆锥形。
2.如权利要求1所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物,其特征在于:
所述可溶美容微针针头长度为150-450μm,微针间距为400-700μm,整个干片包含透明质酸微晶支柱1000-3000个。
3.如权利要求1所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物,其特征在于:
所述无纺布为非织造布,是利用高聚物切片、短纤维或长丝固结而成的;
按照水凝胶贴膜的总重计,所述水凝胶体具体成分为:5-15%的甘油、1-2%的聚丙烯酸钠、1-3%的二羟基甘氨酸铝、0.5-2%的纤维素胶、2-5%的酒石酸、5-15%的丁二醇和50-80%的水;
所述保护薄膜具体为一层白色的塑料膜。
4.权利要求1 至3任一项所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,其特征在于,包括以下步骤:
1)粘稠性液体的制备:
将肌肤祛皱、抗衰老组合物加入余量水中,搅拌溶解,再加入甘油5-15%、低分子量的透明质酸钠2-5%和高分子量的透明质酸钠10-15%,继续搅拌使其溶胀均匀,离心除气泡,即得粘稠性液体;
2)可溶美容微针的制备:
将上述粘稠性液体注入微针模具中,干燥脱模后得到可溶美容微针;
3)水凝胶贴膜的制备:
将1-2%的聚丙烯酸钠和1-3%的二羟基甘氨酸铝混合均匀,加入5-15%的甘油和5-15%的丁二醇充分搅拌,获得A相溶液;
将0.5-2%的纤维素胶加到水中搅拌后加入2-5%的酒石酸,再加入活性组分层,搅拌至充分溶解,获得B相溶液;
将B相溶液加入A相溶液中,真空搅拌获得水凝胶膏体,最后在涂布机上和无纺布、保护薄膜一起进行涂布,制得水凝胶贴膜。
5.如权利要求4所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,其特征在于:
步骤1)中,
高分子量的透明质酸钠和低分子量的透明质酸钠的质量比为1:3.0-5.0。
6.如权利要求4所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,其特征在于:
步骤2)中,所述微针模具包含正方形、矩形或弧形。
7.如权利要求4所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,其特征在于:
步骤2)中,所述干燥的温度为室温,湿度为15-25%,干燥的时间为12-24h。
8.如权利要求4所述的肌肤祛皱、抗衰老可溶美容微针贴膜组合物的制备方法,其特征在于:
步骤3)中,所述真空搅拌的搅拌速度为50-120r/min,搅拌时间为5-15min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111271947.2A CN113813221B (zh) | 2021-10-29 | 2021-10-29 | 一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111271947.2A CN113813221B (zh) | 2021-10-29 | 2021-10-29 | 一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113813221A CN113813221A (zh) | 2021-12-21 |
CN113813221B true CN113813221B (zh) | 2023-11-21 |
Family
ID=78919243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111271947.2A Active CN113813221B (zh) | 2021-10-29 | 2021-10-29 | 一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113813221B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104706553A (zh) * | 2015-02-11 | 2015-06-17 | 广州赛莱拉干细胞科技股份有限公司 | 一种没药叶细胞提取物的提取方法及其应用 |
CN107440934A (zh) * | 2017-07-19 | 2017-12-08 | 广州新济药业科技有限公司 | 抗皮肤衰老的组合物、可溶性微针贴片及其制备方法 |
CN109700691A (zh) * | 2019-03-06 | 2019-05-03 | 大连理工大学 | 一种补水祛皱的微针贴片及其制备方法 |
CN110947088A (zh) * | 2019-12-06 | 2020-04-03 | 广州新济薇娜生物科技有限公司 | 护眼组合贴片及其制备方法 |
CN111481470A (zh) * | 2020-06-09 | 2020-08-04 | 无锡元旭生物技术有限公司 | 用于可溶性微针的水凝胶贴片及其制备方法 |
CN112641656A (zh) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | 一种多肽微针及其制备方法 |
-
2021
- 2021-10-29 CN CN202111271947.2A patent/CN113813221B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104706553A (zh) * | 2015-02-11 | 2015-06-17 | 广州赛莱拉干细胞科技股份有限公司 | 一种没药叶细胞提取物的提取方法及其应用 |
CN107440934A (zh) * | 2017-07-19 | 2017-12-08 | 广州新济药业科技有限公司 | 抗皮肤衰老的组合物、可溶性微针贴片及其制备方法 |
CN109700691A (zh) * | 2019-03-06 | 2019-05-03 | 大连理工大学 | 一种补水祛皱的微针贴片及其制备方法 |
CN110947088A (zh) * | 2019-12-06 | 2020-04-03 | 广州新济薇娜生物科技有限公司 | 护眼组合贴片及其制备方法 |
CN111481470A (zh) * | 2020-06-09 | 2020-08-04 | 无锡元旭生物技术有限公司 | 用于可溶性微针的水凝胶贴片及其制备方法 |
CN112641656A (zh) * | 2020-12-30 | 2021-04-13 | 宇肽生物(东莞)有限公司 | 一种多肽微针及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN113813221A (zh) | 2021-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110664635B (zh) | 一种保湿补水面膜组合物、面膜及其制备方法 | |
CN111388346A (zh) | 一种植物蛋白与多肽配方的冻干粉活面膜及其制备方法 | |
CN105663020A (zh) | 一种具有长效保湿能力的喷雾水及其制备方法 | |
CN104721129A (zh) | 微乳化生物科技护肤品 | |
CN104826228B (zh) | 用于皮肤修复与保养的生物贴 | |
CN110664650A (zh) | 多效护肤组合物和精华液及其制备方法 | |
CN104644500A (zh) | 一种植物保湿组合物及其制备方法 | |
CN111728917A (zh) | 一种护肤品及其制备方法 | |
CN104921961B (zh) | 一种多效修复的可降解生物微针贴 | |
CN103599063A (zh) | 一种抗衰老面霜 | |
CN107929127B (zh) | 一种太子参提取液的制备方法及其在抗皱化妆品中的应用 | |
CN113368018A (zh) | 抗炎祛痘组合物及其制备方法 | |
CN111840201A (zh) | 一种含干细胞因子的抗衰修复复合制剂及其制备方法 | |
CN109010195A (zh) | 一种美白除皱祛疤修复护肤霜及其制备方法 | |
CN106309260B (zh) | 一种三七驻颜面膜 | |
CN111514036A (zh) | 一种提拉紧致抗衰老面膜及其制备方法 | |
CN108309873B (zh) | 赋活均衡调理精华液 | |
CN105560092A (zh) | 一种微修护精华霜及其制备方法 | |
CN113813221B (zh) | 一种肌肤祛皱、抗衰老可溶美容微针贴膜组合物及其制备方法 | |
CN113893197B (zh) | 一种肌肤美白、抗糖化可溶美容微针贴膜组合物及其制备方法 | |
CN116725933A (zh) | 一种美白保湿修复面膜及其制备方法 | |
CN110882177A (zh) | 一种皮肤修复寡肽组合物及其制备方法 | |
CN111437243A (zh) | 一种祛皱抗衰老的组合物、抗衰老化妆品的配方及其制备方法 | |
CN106309172A (zh) | 一种含生物复合肽的抗衰老眼部精华液 | |
CN114767608A (zh) | 一种天然植物养护焕颜复配护肤品原料、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |